Sarepta Therapeutics, Inc. (NASDAQ:SRPT)‘s stock had its “outperform” rating reiterated by investment analysts at Robert W. Baird in a research report issued on Wednesday. They presently have a $101.00 price target on the biotechnology company’s stock. Robert W. Baird’s price objective suggests a potential upside of 134.83% from the company’s previous close.

SRPT has been the subject of several other research reports. Janney Montgomery Scott increased their price target on shares of Sarepta Therapeutics from $65.00 to $73.00 and gave the company a “fair value” rating in a research note on Monday, July 24th. Vetr cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating and set a $36.86 price target for the company. in a research note on Monday, May 22nd. Credit Suisse Group reissued an “outperform” rating and issued a $64.00 price target on shares of Sarepta Therapeutics in a research note on Friday, June 30th. Nomura reissued a “buy” rating and issued a $84.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, May 23rd. Finally, Zacks Investment Research cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, July 17th. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. Sarepta Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $62.31.

Sarepta Therapeutics (NASDAQ:SRPT) traded down 5.22% on Wednesday, reaching $43.01. The company had a trading volume of 2,882,617 shares. The firm’s market capitalization is $2.77 billion. Sarepta Therapeutics has a 1-year low of $25.47 and a 1-year high of $63.73. The company’s 50-day moving average price is $39.34 and its 200 day moving average price is $34.16.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.46. The business had revenue of $35.01 million for the quarter, compared to analysts’ expectations of $22.52 million. During the same period in the prior year, the company posted ($1.19) EPS. The firm’s revenue was up 350000.0% on a year-over-year basis. On average, equities analysts forecast that Sarepta Therapeutics will post ($1.23) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Sarepta Therapeutics, Inc. (SRPT) Rating Reiterated by Robert W. Baird” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/10/sarepta-therapeutics-inc-srpt-rating-reiterated-by-robert-w-baird.html.

In other news, CEO Douglas S. Ingram acquired 47,058 shares of Sarepta Therapeutics stock in a transaction dated Thursday, July 27th. The shares were acquired at an average cost of $42.50 per share, for a total transaction of $1,999,965.00. Following the acquisition, the chief executive officer now owns 382,058 shares of the company’s stock, valued at $16,237,465. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Shamim Ruff sold 12,138 shares of the firm’s stock in a transaction on Friday, July 21st. The shares were sold at an average price of $42.97, for a total transaction of $521,569.86. Following the completion of the sale, the senior vice president now owns 27,312 shares in the company, valued at $1,173,596.64. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 78,056 shares of company stock worth $3,224,208. 9.60% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Asymmetry Capital Management L.P. raised its holdings in shares of Sarepta Therapeutics by 82.2% in the 2nd quarter. Asymmetry Capital Management L.P. now owns 158,810 shares of the biotechnology company’s stock valued at $5,353,000 after purchasing an additional 71,630 shares in the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of Sarepta Therapeutics by 6.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 271 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its holdings in shares of Sarepta Therapeutics by 85.8% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 20,871 shares of the biotechnology company’s stock valued at $704,000 after purchasing an additional 9,635 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Sarepta Therapeutics by 3.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 40,188 shares of the biotechnology company’s stock valued at $1,355,000 after purchasing an additional 1,435 shares in the last quarter. Finally, Osterweis Capital Management Inc. acquired a new stake in shares of Sarepta Therapeutics in the 2nd quarter valued at $3,806,000. Institutional investors and hedge funds own 65.43% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.